CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.560
+0.090 (3.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
CytoMed Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for GDTC stock has a target of 5.00, which predicts an increase of 95.31% from the current stock price of 2.56.
Analyst Consensus: Buy
* Price targets were last updated on Oct 10, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for GDTC is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +95.31% | Oct 10, 2024 |
| Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +95.31% | Jun 11, 2024 |
| Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +95.31% | Dec 4, 2023 |
| Benchmark | Benchmark | Buy Initiates $5 | Buy | Initiates | $5 | +95.31% | Jul 21, 2023 |
Financial Forecast
Revenue This Year
582.42K
from 507.74K
Increased by 14.71%
Revenue Next Year
530.40K
from 582.42K
Decreased by -8.93%
EPS This Year
-0.15
from -0.39
EPS Next Year
-0.17
from -0.15
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 599,550 | 546,000 |
| Avg | 582,420 | 530,400 |
| Low | 559,580 | 509,600 |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 18.1% | -6.3% |
| Avg | 14.7% | -8.9% |
| Low | 10.2% | -12.5% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -0.16 | -0.18 |
| Avg | -0.15 | -0.17 |
| Low | -0.15 | -0.17 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.